Should I buy or sell Nkarta stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares. View NKTX analyst ratings or view top-rated stocks .

What is Nkarta's stock price target for 2024?

5 equities research analysts have issued 12-month price objectives for Nkarta's stock. Their NKTX share price targets range from $15.00 to $25.00. On average, they predict the company's share price to reach $17.83 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price. View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts .

How have NKTX shares performed in 2024?

Nkarta's stock was trading at $6.60 at the beginning of 2024. Since then, NKTX stock has increased by 11.1% and is now trading at $7.33. View the best growth stocks for 2024 here .

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NKTX earnings forecast .

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) released its earnings results on Thursday, March, 21st. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.05.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA) , Cronos Group (CRON) , Block (SQ) , Advanced Micro Devices (AMD) , ASML (ASML) , Beyond Meat (BYND) , Citigroup (C) , Salesforce (CRM) , CVS Health (CVS) and DraftKings (DKNG) .

Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (2.36%) and Denali Advisors LLC (0.05%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam , Nadir Mahmood , Paul J Hastings, Paul J Hastings , Ra Capital Management, LP, Ralph Brandenberger and Simeon George. View institutional ownership trends .

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

→ 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad)

Free NKTX Stock Alerts

$7.33

-0.46 (-5.91%)

(As of 01:52 PM ET)

Compare

Today's Range: $7.24
▼
$7.96
50-Day Range: $7.79
▼
$15.71
52-Week Range: $1.28
▼
$16.24

Volume: 377,050 shs
Average Volume: 1.91 million shs
Market Capitalization: $362.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.83

Get Nkarta alerts:

Nkarta MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 143.3% Upside
$17.83 Price Target
Short Interest: Bearish
9.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.34) to ($2.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

381st out of 918 stocks

Pharmaceutical Preparations Industry

168th out of 419 stocks

4.5

Analyst's Opinion

Consensus Rating
Nkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Nkarta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
9.81% of the outstanding shares of Nkarta have been sold short.
Short Interest Ratio / Days to Cover
Nkarta has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nkarta has recently increased by 16.03%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nkarta does not currently pay a dividend.
Dividend Growth
Nkarta does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NKTX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Nkarta this week, compared to 2 articles on an average week.
Search Interest
Only 25 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nkarta insiders have bought 40,128.50% more of their company's stock than they have sold. Specifically, they have bought $20,000,000.00 in company stock and sold $49,716.00 in company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Nkarta is held by insiders.
Percentage Held by Institutions
80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Nkarta are expected to grow in the coming year, from ($2.34) to ($2.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nkarta is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nkarta is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nkarta has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

[Get Your Insights Now]

About Nkarta Stock (NASDAQ:NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NKTX Stock News Headlines

March 30, 2024 | insidertrades.com

Simeon George Purchases 2,000,000 Shares of Nkarta, Inc. (NASDAQ:NKTX) Stock

April 18, 2024 | finance.yahoo.com

Nkarta, Inc. (NKTX) Interactive Stock Chart - Yahoo Finance

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

April 11, 2024 | americanbankingnews.com

Nkarta's (NKTX) Buy Rating Reiterated at Needham & Company LLC

April 10, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)

April 10, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)

April 8, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

April 5, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 5, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

April 3, 2024 | globenewswire.com

Nkarta to Participate in Upcoming Investor Conferences

March 31, 2024 | 247wallst.com

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

March 27, 2024 | markets.businessinsider.com

TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)

March 27, 2024 | msn.com

Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-Hearted

March 26, 2024 | sg.finance.yahoo.com

Nkarta, Inc. (NKTX) interactive stock chart – Yahoo Finance

March 25, 2024 | seekingalpha.com

Nkarta: NK Cell Therapy Advancement On Two Fronts

March 25, 2024 | msn.com

Nkarta announces pricing of stock offering to raise $240.1M

March 25, 2024 | markets.businessinsider.com

Nkarta Prices $240 Mln Offering; Stock Up Over 16%

March 25, 2024 | globenewswire.com

Nkarta Announces Pricing of $240 Million Underwritten Offering

March 25, 2024 | markets.businessinsider.com

Nkarta’s Strategic Pivot to CAR-NK Therapies for Autoimmune Diseases Prompts Buy Rating

March 23, 2024 | finance.yahoo.com

Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment

March 22, 2024 | finanznachrichten.de

Nkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

March 22, 2024 | markets.businessinsider.com

Buy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease Treatment

March 22, 2024 | markets.businessinsider.com

Nkarta’s Strategic Focus and Financial Strength Underpin Buy Rating

March 22, 2024 | msn.com

These Analysts Revise Their Forecasts On Nkarta After Q4 Results

March 21, 2024 | investorplace.com

NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023

March 21, 2024 | globenewswire.com

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

See More Headlines

Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NKTX
CUSIP: N/A
CIK: 1787400
Web: www.nkartatx.com
Phone: 925-407-1049
Fax: N/A
Employees: 150
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.83
High Stock Price Target: $25.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +128.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-117,500,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.06%
Return on Assets: -28.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.85
Quick Ratio: 10.85

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.57 per share
Price / Book: 1.40

Miscellaneous

Outstanding Shares: 49,420,000
Free Float: 46,649,000
Market Cap: $384.98 million
Optionable: Optionable
Beta: 0.70

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Paul J. Hastings (Age 64)
CEO, President & Director
Comp: $938.41k
Dr. Alicia J. Hager (Age 54)
Chief Legal Officer & Corporate Secretary
Comp: $590.94k
Ms. Alyssa Levin C.A. (Age 39)
CPA, Chief Financial & Business Officer and Principal Accounting Officer
Dr. Ralph Brandenberger Ph.D. (Age 55)
Chief Technical Officer
Dr. James Trager Ph.D. (Age 61)
Chief Scientific Officer
Mr. Greg Mann
Vice President of Public Affairs and Investor Relations
Dr. David R. Shook M.D. (Age 46)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares.
View NKTX analyst ratings or view top-rated stocks.
What is Nkarta's stock price target for 2024?: 5 equities research analysts have issued 12-month price objectives for Nkarta's stock. Their NKTX share price targets range from $15.00 to $25.00. On average, they predict the company's share price to reach $17.83 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price.
View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts.
How have NKTX shares performed in 2024?: Nkarta's stock was trading at $6.60 at the beginning of 2024. Since then, NKTX stock has increased by 11.1% and is now trading at $7.33.
View the best growth stocks for 2024 here.
When is Nkarta's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NKTX earnings forecast.
How were Nkarta's earnings last quarter?: Nkarta, Inc. (NASDAQ:NKTX) released its earnings results on Thursday, March, 21st. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.05.

What other stocks do shareholders of Nkarta own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).
When did Nkarta IPO?: Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.
Who are Nkarta's major shareholders?: Nkarta's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (2.36%) and Denali Advisors LLC (0.05%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends.
How do I buy shares of Nkarta?: Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial